Drug Approval | January 28, 2024
Shilpa Medicare updates on Europe GMP inspection at Unit 4, Jadcherla, Telangana
The company intends to respond to the two minor observations within the stipulated time
The company intends to respond to the two minor observations within the stipulated time
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The registered capital of the newly founded company is € 50 million
Dr. Mandaviya also laid the foundation stone for an All India Institute of Speech and Hearing (AIISH) Satellite Centre in Kanpur
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Aarti Drugs has reported total income of Rs. 607.61 crores during the period ended December 31, 2023
The company also plans to boost its India presence by adding 1,500 beds in the next 2-3 years
Cipla has reported total income of Rs. 6,788.44 crores during the period ended December 31, 2023
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
GC1130A has previously achieved notable milestones by securing both RPDD and ODD from the U.S. FDA in January 2023
Subscribe To Our Newsletter & Stay Updated
